A 30-year-old man with schizophrenia stabilized on clozapine presents to establish care at a new clinic. Records show stable psychiatric symptoms for 2 years. Routine urine drug screen is positive for cocaine. He admits to using cocaine 2-3 times monthly at parties but denies it affects his functioning. He has maintained employment, housing, and medication adherence. He refuses substance use treatment, stating 'it's recreational and under control.' His last clozapine level was therapeutic. Evaluate the management approach balancing psychiatric stability, substance use, and patient autonomy.
Q2
A 42-year-old physician presents voluntarily to the state physician health program after colleagues noticed erratic behavior. He admits to diverting fentanyl from the operating room for 18 months, using it to manage work stress. He has no prior substance use history, maintains he can 'handle it,' but acknowledges his medical license and career are at risk. He completed detoxification last week. Evaluate the comprehensive management strategy that addresses medical, professional, and legal considerations.
Q3
A 26-year-old pregnant woman at 16 weeks gestation with opioid use disorder requests medication-assisted treatment. She has been using heroin daily for 3 years and is motivated for treatment. She has tried 'quitting cold turkey' previously but relapsed within days. Obstetrics has referred her urgently for addiction medicine consultation. Evaluate the treatment approach that optimizes both maternal and fetal outcomes.
Q4
A 50-year-old man with alcohol use disorder presents for the third time in 6 months with alcohol-related pancreatitis. He has completed detoxification twice, attended some AA meetings, but relapsed each time. He has compensated cirrhosis (Child-Pugh A) and is motivated to quit. Lab shows AST 95, ALT 60, GGT 180. He requests 'something that will make me sick if I drink.' Analyze the treatment options and select the most evidence-based pharmacotherapy.
Q5
A 19-year-old woman is brought to the ED after being found unresponsive at a party. She is minimally responsive with pinpoint pupils, respiratory rate of 6 breaths per minute, and oxygen saturation of 85% on room air. Friends report possible heroin use. After naloxone administration, she becomes combative and wants to leave. Her respiratory rate is now 14 and she is fully alert. Analyze the risks and determine appropriate management.
Q6
A 35-year-old man with chronic pain from a work injury has been prescribed oxycodone 30 mg four times daily for 2 years. He now requests early refills every month, reports escalating use, and his wife states he is 'not himself' and neglecting family responsibilities. He denies problems and insists he needs higher doses. Pain clinic notes show normal examinations and imaging. Analyze the clinical situation and determine the most appropriate next step.
Q7
A 22-year-old college student presents with anxiety, paranoia, and auditory hallucinations that started 3 days ago. Friends report he has been using 'study drugs' heavily during finals week. Vitals show BP 145/90 mmHg, HR 105 bpm, temperature 37.8°C. He is picking at his skin and appears hypervigilant. Urine drug screen is positive for amphetamines. What is the most appropriate initial management approach?
Q8
A 45-year-old homeless man is brought to the emergency department confused and ataxic. He has nystagmus and ophthalmoplegia. Serum glucose is 85 mg/dL. The intern orders IV dextrose for presumed hypoglycemia. Before the dextrose is administered, what critical intervention must be provided?
Q9
A 28-year-old woman with opioid use disorder has been maintained on buprenorphine-naloxone 16/4 mg daily for 6 months with good adherence and negative urine drug screens. She now presents requesting to taper off medication as she feels 'cured' and wants to try sobriety without medication. She has stable housing and employment. What is the most appropriate response?
Q10
A 32-year-old man presents to the emergency department with severe anxiety, tremor, diaphoresis, and elevated blood pressure (160/95 mmHg). His wife reports he has been drinking heavily for the past 5 years and stopped abruptly 24 hours ago. On examination, he is oriented but restless, with a heart rate of 110 bpm. He has no seizure history. What is the most appropriate initial pharmacological management?
Substance use disorders US Medical PG Practice Questions and MCQs
Question 1: A 30-year-old man with schizophrenia stabilized on clozapine presents to establish care at a new clinic. Records show stable psychiatric symptoms for 2 years. Routine urine drug screen is positive for cocaine. He admits to using cocaine 2-3 times monthly at parties but denies it affects his functioning. He has maintained employment, housing, and medication adherence. He refuses substance use treatment, stating 'it's recreational and under control.' His last clozapine level was therapeutic. Evaluate the management approach balancing psychiatric stability, substance use, and patient autonomy.
A. Mandate substance use treatment as condition for continuing clozapine
B. Switch to long-acting injectable antipsychotic with lower risk profile
C. Discontinue clozapine due to medication non-compliance and substance use risk
D. Continue clozapine with harm reduction counseling, more frequent monitoring, and motivational interviewing for substance use (Correct Answer)
E. Involuntarily hospitalize for dual diagnosis treatment program
Explanation: ***Continue clozapine with harm reduction counseling, more frequent monitoring, and motivational interviewing for substance use***
- The patient has been **psychiatrically stable** on clozapine for two years and maintains high functioning; discontinuing a life-saving medication for **treatment-resistant schizophrenia** due to intermittent substance use risks severe decompensation.
- A **harm reduction** approach utilizing **motivational interviewing** addresses the cocaine use without damaging the therapeutic alliance, while **increased monitoring** manages potential risks like a **lowered seizure threshold** or cardiac strain.
*Mandate substance use treatment as condition for continuing clozapine*
- Coercive strategies often lead to **patient dropout** and treatment non-adherence, which could result in a relapse of psychosis.
- Medical ethics prioritize **patient autonomy**; treatment mandates are generally reserved for situations where the patient lacks capacity or poses an immediate danger.
*Switch to long-acting injectable antipsychotic with lower risk profile*
- **Clozapine** is uniquely effective for patients who have failed other treatments; switching a stable patient to a **long-acting injectable (LAI)** may lead to a loss of symptom control.
- The patient's **medication adherence** is already documented as excellent, so the primary benefit of an LAI—improving compliance—is not a current clinical priority.
*Discontinue clozapine due to medication non-compliance and substance use risk*
- The patient is actually **compliant** with his clozapine regimen, as evidenced by his **therapeutic drug levels** and stable psychiatric status.
- Discontinuation represents a high-risk clinical decision that ignores the **biopsychosocial stability** the patient has achieved despite his recreational drug use.
*Involuntarily hospitalize for dual diagnosis treatment program*
- **Involuntary hospitalization** requires the patient to be a **danger to self or others** or be gravely disabled, none of which apply to this stable, employed individual.
- Forced treatment for substance use is not legally supported in this context and would be a significant overreach that violates **civil liberties**.
Question 2: A 42-year-old physician presents voluntarily to the state physician health program after colleagues noticed erratic behavior. He admits to diverting fentanyl from the operating room for 18 months, using it to manage work stress. He has no prior substance use history, maintains he can 'handle it,' but acknowledges his medical license and career are at risk. He completed detoxification last week. Evaluate the comprehensive management strategy that addresses medical, professional, and legal considerations.
A. Intensive outpatient treatment, peer support, naltrexone, monitored return-to-work agreement, and restricted practice for minimum 1-2 years (Correct Answer)
B. Outpatient naltrexone therapy with weekly random drug screens and return to work in 3 months
C. Immediate return to practice with mandatory addiction counseling and quarterly monitoring
D. 6-month residential treatment followed by career change recommendation due to access to controlled substances
E. Report to medical board for license revocation due to diversion and patient safety risk
Explanation: ***Intensive outpatient treatment, peer support, naltrexone, monitored return-to-work agreement, and restricted practice for minimum 1-2 years***
- Physician health programs (PHPs) mandate a high-intensity approach including **monitored return-to-work** and **restricted practice** to ensure patient safety and professional accountability.
- Long-term success is achieved through **multi-modal therapy**, which includes Pharmacotherapy (like **naltrexone**), **peer support groups**, and frequent **random drug screening**.
*Outpatient naltrexone therapy with weekly random drug screens and return to work in 3 months*
- This approach is insufficient as it lacks the **intensive structural support** and specific **practice restrictions** required for a high-risk role like an anesthesiologist.
- Returning to work in such a short timeframe without a formal **physician health program (PHP)** monitoring contract significantly increases the risk of **relapse**.
*Immediate return to practice with mandatory addiction counseling and quarterly monitoring*
- **Immediate return** is unsafe because the physician has recently diverted **fentanyl**, posing a direct risk to **patient safety** and his own health.
- **Quarterly monitoring** is too infrequent for early recovery; high-frequency **random drug screens** are standard to detect early diversion or relapse.
*6-month residential treatment followed by career change recommendation due to access to controlled substances*
- While **residential treatment** is an option, a **career change recommendation** is generally not required if the physician complies with a **restrictive monitoring agreement**.
- Most physicians can safely return to their specialty after successful **rehabilitation** and a period of **restricted access** to controlled substances.
*Report to medical board for license revocation due to diversion and patient safety risk*
- **Licensure revocation** is typically a last resort; many states encourage **voluntary participation** in PHPs to help physicians recover while maintaining their license.
- Reporting and revocation are usually reserved for cases where the physician **refuses treatment**, fails to comply with monitoring, or causes **direct patient harm**.
Question 3: A 26-year-old pregnant woman at 16 weeks gestation with opioid use disorder requests medication-assisted treatment. She has been using heroin daily for 3 years and is motivated for treatment. She has tried 'quitting cold turkey' previously but relapsed within days. Obstetrics has referred her urgently for addiction medicine consultation. Evaluate the treatment approach that optimizes both maternal and fetal outcomes.
A. Buprenorphine initiation with obstetric monitoring and prenatal care coordination
B. Medically supervised withdrawal to avoid fetal exposure to maintenance medications
C. Naltrexone implant after medically supervised opioid detoxification
D. Methadone maintenance with daily observed dosing at licensed clinic (Correct Answer)
E. Delay treatment until second trimester completion to minimize teratogenic risk
Explanation: ***Methadone maintenance with daily observed dosing at licensed clinic***
- **Methadone** is the gold standard for opioid use disorder in pregnancy, providing a stable environment for the fetus by preventing **cycles of withdrawal** and illicit drug use.
- It is associated with improved **prenatal care** adherence and significantly reduced risks of **preterm labor** and **fetal demise** compared to untreated addiction.
*Buprenorphine initiation with obstetric monitoring and prenatal care coordination*
- While **buprenorphine** is a valid alternative, **methadone** remains the traditional first-line choice due to more extensive, long-term **safety data** regarding pregnancy outcomes.
- Buprenorphine is often preferred for lower severity cases, but the structured support of a **methadone clinic** is better for patients with long-term, high-frequency **heroin use**.
*Medically supervised withdrawal to avoid fetal exposure to maintenance medications*
- Withdrawal or "detox" during pregnancy carries a very high rate of **relapse**, which exposes the fetus to dangerous **stress and toxicity**.
- Stable maintenance therapy is preferred over withdrawal to prevent the severe maternal-fetal complications associated with **resumed illicit opioid use**.
*Naltrexone implant after medically supervised opioid detoxification*
- **Naltrexone** is generally avoided in pregnancy because it requires a complete **detoxification** phase, which triggers maternal-fetal distress.
- There is insufficient safety data regarding the use of **naltrexone implants** or long-acting formulations in pregnant patients compared to agonist therapies.
*Delay treatment until second trimester completion to minimize teratogenic risk*
- Opioid maintenance medications like methadone and buprenorphine are not considered **teratogenic**, and delaying treatment increases the risk of **fetal loss**.
- Treatment should be initiated as soon as possible to stabilize the **maternal-fetal unit** and reduce the risks associated with active addiction and infectious disease exposure.
Question 4: A 50-year-old man with alcohol use disorder presents for the third time in 6 months with alcohol-related pancreatitis. He has completed detoxification twice, attended some AA meetings, but relapsed each time. He has compensated cirrhosis (Child-Pugh A) and is motivated to quit. Lab shows AST 95, ALT 60, GGT 180. He requests 'something that will make me sick if I drink.' Analyze the treatment options and select the most evidence-based pharmacotherapy.
A. Naltrexone 50 mg daily to reduce craving and rewarding effects (Correct Answer)
B. Disulfiram 250 mg daily with close monitoring
C. Acamprosate 666 mg three times daily for abstinence maintenance
D. Topiramate 200 mg daily for craving reduction
E. Gabapentin 1800 mg daily in divided doses
Explanation: ***Naltrexone 50 mg daily to reduce craving and rewarding effects***
- **Naltrexone** is a first-line treatment that blocks **mu-opioid receptors**, effectively reducing the reinforcing "high" of alcohol and decreasing the frequency of heavy drinking.
- While the patient has elevated liver enzymes, it is generally safe in **Child-Pugh A** cirrhosis; it is often preferred over other agents due to its robust efficacy in preventing relapse.
*Disulfiram 250 mg daily with close monitoring*
- Although the patient requested it, **Disulfiram** carries a risk of **hepatotoxicity**, making it a risky choice for someone with pre-existing **cirrhosis** and active liver inflammation.
- It acts as an **aldehyde dehydrogenase inhibitor**, causing a severe physical reaction to alcohol, but it does not address the underlying craving and has lower evidence-based success rates compared to Naltrexone.
*Acamprosate 666 mg three times daily for abstinence maintenance*
- **Acamprosate** modulates the **glutamatergic system** and is excellent for maintaining abstinence, but the **three-times-daily** dosing schedule often leads to poor medication adherence.
- It is primarily cleared by the kidneys and would be a preferred choice if the patient had significant **liver failure** or renal impairment, but Naltrexone is generally prioritized for initial craving reduction.
*Topiramate 200 mg daily for craving reduction*
- **Topiramate** is an anti-epileptic drug used **off-label** for alcohol use disorder to reduce heavy drinking days and cravings.
- It is considered a second-line option because its evidence base is less robust than that of **FDA-approved** medications like Naltrexone and Acamprosate.
*Gabapentin 1800 mg daily in divided doses*
- **Gabapentin** is used **off-label** and may help with alcohol withdrawal symptoms and minor craving reduction, especially in patients with co-morbid insomnia or anxiety.
- High doses are required for efficacy, and it is not considered first-line therapy for a patient with multiple relapses and significant medical complications like **pancreatitis**.
Question 5: A 19-year-old woman is brought to the ED after being found unresponsive at a party. She is minimally responsive with pinpoint pupils, respiratory rate of 6 breaths per minute, and oxygen saturation of 85% on room air. Friends report possible heroin use. After naloxone administration, she becomes combative and wants to leave. Her respiratory rate is now 14 and she is fully alert. Analyze the risks and determine appropriate management.
A. Restrain and admit for 72-hour psychiatric hold for substance abuse
B. Allow her to leave as she has decision-making capacity and is no longer in acute danger
C. Observe for at least 4-6 hours due to naloxone's shorter half-life than most opioids (Correct Answer)
D. Discharge with naloxone prescription and outpatient addiction treatment referral
E. Administer long-acting naltrexone injection before discharge
Explanation: ***Observe for at least 4-6 hours due to naloxone's shorter half-life than most opioids***
- **Naloxone** has a relatively short half-life (30–90 minutes), which is shorter than many opioids like **heroin** or long-acting synthetics; this creates a risk of **re-narcotization** as the antagonist wears off.
- A 4–6 hour observation period is the standard of care to ensure the patient does not relapse into **respiratory depression** or apnea once the naloxone effects dissipate.
*Restrain and admit for 72-hour psychiatric hold for substance abuse*
- Substance abuse alone without evidence of **acute suicidality** or inability to care for oneself does not typically meet legal criteria for an **involuntary psychiatric hold**.
- While the patient is combative, this is often a symptom of **acute opioid withdrawal** precipitated by naloxone rather than a primary psychiatric emergency.
*Allow her to leave as she has decision-making capacity and is no longer in acute danger*
- Although the patient is currently alert, she remains in **acute danger** because the opioid may outlast the naloxone, leading to a recurrence of **overdose symptoms**.
- Medical providers have a duty to ensure the patient remains stable; discharging a patient who is at high risk of **re-sedation** can be considered medical negligence.
*Discharge with naloxone prescription and outpatient addiction treatment referral*
- While providing a **take-home naloxone kit** and addiction referrals are vital components of long-term care, they do not mitigate the **immediate risk** of the current overdose recurring.
- Discharge is only appropriate after a sufficient period of observation (usually 4–6 hours) has passed without a return of **CNS depression**.
*Administer long-acting naltrexone injection before discharge*
- **Naltrexone** is an opioid antagonist used for long-term maintenance and is strictly contraindicated in patients who are currently **opioid-dependent** or have used opioids recently.
- Administering naltrexone in this setting would precipitate severe, prolonged, and potentially life-threatening **acute withdrawal symptoms**.
Question 6: A 35-year-old man with chronic pain from a work injury has been prescribed oxycodone 30 mg four times daily for 2 years. He now requests early refills every month, reports escalating use, and his wife states he is 'not himself' and neglecting family responsibilities. He denies problems and insists he needs higher doses. Pain clinic notes show normal examinations and imaging. Analyze the clinical situation and determine the most appropriate next step.
A. Abruptly discontinue opioids due to misuse behaviors
B. Increase oxycodone dose to achieve adequate pain control
C. Transition to buprenorphine for pain management and opioid use disorder treatment (Correct Answer)
D. Refer to pain psychology and continue current opioid regimen
E. Switch to long-acting fentanyl patch for better compliance
Explanation: ***Transition to buprenorphine for pain management and opioid use disorder treatment***
- The patient exhibits core criteria for **Opioid Use Disorder (OUD)**, including loss of control over use, functional impairment at home, and escalating doses despite documented normal imaging and examinations.
- **Buprenorphine** is a partial mu-opioid agonist that effectively manages **chronic pain** while simultaneously treating **OUD** by reducing cravings and preventing withdrawal.
*Abruptly discontinue opioids due to misuse behaviors*
- Immediate cessation of chronic high-dose opioids can trigger severe **withdrawal symptoms**, which may lead to dangerous medical complications or high-risk illicit drug seeking.
- Best practice involves a guided transition to **medication-assisted treatment** or a very regulated taper rather than abrupt termination.
*Increase oxycodone dose to achieve adequate pain control*
- Escalating the dose in a patient showing signs of addiction and **functional decline** typically worsens the **opioid use disorder** and increases the risk of overdose.
- Since imaging and physical exams are stable, the request for higher doses likely represents **opioid tolerance** or addictive behavior rather than new physical pathology.
*Refer to pain psychology and continue current opioid regimen*
- While **psychological support** is an important adjunct, it is insufficient as a standalone solution when active **opioid misuse** and functional neglect are present.
- Continuing the current regimen ignores the immediate safety risk and the established diagnosis of **opioid use disorder**.
*Switch to long-acting fentanyl patch for better compliance*
- Switching to another **full mu-opioid agonist** like fentanyl does not address the underlying neurobiological addiction and may increase the risk of **respiratory depression**.
- Long-acting full agonists do not provide the ceiling effect for respiratory depression that makes **buprenorphine** a safer alternative in misuse cases.
Question 7: A 22-year-old college student presents with anxiety, paranoia, and auditory hallucinations that started 3 days ago. Friends report he has been using 'study drugs' heavily during finals week. Vitals show BP 145/90 mmHg, HR 105 bpm, temperature 37.8°C. He is picking at his skin and appears hypervigilant. Urine drug screen is positive for amphetamines. What is the most appropriate initial management approach?
A. Low-dose haloperidol for acute psychotic symptoms
B. Admit to psychiatry unit for first-episode psychosis workup
C. Benzodiazepines for agitation with supportive care in quiet environment (Correct Answer)
D. Discharge with outpatient psychiatry follow-up once medically stable
E. Start aripiprazole for stimulant-induced psychosis
Explanation: ***Benzodiazepines for agitation with supportive care in quiet environment***
- **Benzodiazepines** are the first-line treatment for managing agitation and **autonomic instability** (tachycardia, hypertension) in stimulant-induced toxicity.
- Initial management focuses on a **low-stimulation environment** to prevent worsening of hypervigilance and paranoia while the drug is cleared from the system.
*Low-dose haloperidol for acute psychotic symptoms*
- While effective for psychosis, **haloperidol** should be used cautiously as it can lower the **seizure threshold**, which is already a risk in amphetamine overdose.
- It may also interfere with **thermoregulation**, potentially worsening the hyperthermia often seen in stimulant toxicity.
*Admit to psychiatry unit for first-episode psychosis workup*
- Routine admission for **first-episode psychosis** is premature when a clear toxicological cause (**positive urine drug screen**) is identified.
- Psychotic symptoms usually resolve within **3 to 7 days** as the stimulant is metabolized, making medical stabilization the priority.
*Discharge with outpatient psychiatry follow-up once medically stable*
- Discharge is inappropriate while the patient is still **hypervigilant, paranoid**, and experiencing hallucinations, as he may pose a risk to himself or others.
- Observation is required to ensure that **autonomic symptoms** and psychosis resolve safely without progression to cardiovascular complications or delirium.
*Start aripiprazole for stimulant-induced psychosis*
- Long-term **second-generation antipsychotics** are not indicated for acute intoxication, as symptoms are typically transient and self-limiting.
- The priority is **acute symptom control** and safety; maintenance medications are deferred until it is determined if a primary psychotic disorder exists.
Question 8: A 45-year-old homeless man is brought to the emergency department confused and ataxic. He has nystagmus and ophthalmoplegia. Serum glucose is 85 mg/dL. The intern orders IV dextrose for presumed hypoglycemia. Before the dextrose is administered, what critical intervention must be provided?
A. Administer thiamine 100 mg IV before any dextrose (Correct Answer)
B. Perform CT head to rule out intracranial hemorrhage
C. Obtain blood alcohol level and comprehensive metabolic panel
D. Administer naloxone 0.4 mg IV for possible opioid intoxication
E. Start IV normal saline for presumed dehydration
Explanation: ***Administer thiamine 100 mg IV before any dextrose***
- This patient presents with the classic triad of **Wernicke encephalopathy**: confusion, **ataxia**, and ophthalmoplegia/nystagmus, common in chronic alcoholism.
- Administering **dextrose** before **thiamine** can acutely worsen the condition because thiamine is a required cofactor for glucose metabolism pathways, and an influx of glucose rapidly depletes remaining thiamine stores.
*Perform CT head to rule out intracranial hemorrhage*
- While trauma or hemorrhage are possibilities in a homeless patient, the neurologic signs and presentation are more characteristic of **metabolic deficiencies** associated with malnutrition.
- A CT scan would delay the critical immediate treatment needed to prevent progression to permanent **Korsakoff syndrome**.
*Obtain blood alcohol level and comprehensive metabolic panel*
- Laboratory diagnostics should be performed, but clinical diagnosis of **thiamine deficiency** requires immediate intervention without waiting for results.
- These tests provide baseline information but do not address the acute risk of **precipitating encephalopathy** with glucose administration.
*Administer naloxone 0.4 mg IV for possible opioid intoxication*
- Opioid overdose typically presents with **miosis** (pinpoint pupils) and **respiratory depression**, which are not described in this patient.
- **Naloxone** will not address the localized neurological signs like **nystagmus** or the underlying nutritional deficiency.
*Start IV normal saline for presumed dehydration*
- While fluid resuscitation is often necessary, it does not prioritize the metabolic emergency of **thiamine depletion**.
- Administering fluids alone does not protect the brain from the damage caused by **glucose-induced thiamine exhaustion**.
Question 9: A 28-year-old woman with opioid use disorder has been maintained on buprenorphine-naloxone 16/4 mg daily for 6 months with good adherence and negative urine drug screens. She now presents requesting to taper off medication as she feels 'cured' and wants to try sobriety without medication. She has stable housing and employment. What is the most appropriate response?
A. Support immediate discontinuation since she has been stable for 6 months
B. Switch to naltrexone implant for long-term relapse prevention
C. Discuss the evidence that longer-term maintenance improves outcomes and risk of relapse with discontinuation (Correct Answer)
D. Require 12 months of stability before considering any taper
E. Refer to residential treatment program for medication discontinuation
Explanation: ***Discuss the evidence that longer-term maintenance improves outcomes and risk of relapse with discontinuation***
- Research indicates that **longer-term maintenance therapy** (typically 12 months or longer) is associated with significantly lower **relapse rates** and decreased **overdose mortality** compared to short-term treatment.
- Shared decision-making requires the physician to inform the patient that while they feel stable, **premature discontinuation** often leads to a return to use even in those with stable social factors.
*Support immediate discontinuation since she has been stable for 6 months*
- **Immediate discontinuation** carries a very high risk of **opioid withdrawal** and subsequent relapse to illicit opioid use.
- Stability on medication for 6 months is an indicator that the **medication is working**, not necessarily that the underlying **neurobiological changes** of addiction have resolved.
*Switch to naltrexone implant for long-term relapse prevention*
- Transitioning to **naltrexone** requires a complete detox period from all opioids; an immediate switch would precipitate **severe withdrawal** in a patient currently on buprenorphine.
- **Naltrexone implants** are not the first-line recommendation for a patient currently succeeding on a **partial agonist** like buprenorphine.
*Require 12 months of stability before considering any taper*
- While 12 months is often used as a clinical milestone, setting a **rigid or mandatory timeline** can undermine the **therapeutic alliance** and patient autonomy.
- The decision to taper should be based on a **comprehensive risk assessment** and patient preference rather than an arbitrary administrative rule.
*Refer to residential treatment program for medication discontinuation*
- **Residential treatment** is generally reserved for patients with unstable housing, lack of social support, or failure of **outpatient management**, which does not apply to this patient.
- Discontinuing medication in a **structured setting** does not mitigate the long-term risk of **relapse** once the patient returns to their daily environment.
Question 10: A 32-year-old man presents to the emergency department with severe anxiety, tremor, diaphoresis, and elevated blood pressure (160/95 mmHg). His wife reports he has been drinking heavily for the past 5 years and stopped abruptly 24 hours ago. On examination, he is oriented but restless, with a heart rate of 110 bpm. He has no seizure history. What is the most appropriate initial pharmacological management?
A. Haloperidol 5 mg intramuscularly
B. Thiamine 100 mg followed by dextrose infusion
C. Lorazepam 2 mg intravenously with CIWA protocol (Correct Answer)
D. Propranolol 40 mg orally for autonomic symptoms
E. Disulfiram 250 mg daily to prevent relapse
Explanation: ***Lorazepam 2 mg intravenously with CIWA protocol***
- **Benzodiazepines** are the first-line treatment for **alcohol withdrawal syndrome** as they provide cross-tolerance to alcohol and reduce the risk of seizures and delirium tremens.
- The **CIWA (Clinical Institute Withdrawal Assessment)** protocol allows for **symptom-triggered therapy**, which is more effective and requires less medication than fixed-schedule dosing.
*Haloperidol 5 mg intramuscularly*
- Antipsychotics like haloperidol are generally avoided as mono-therapy because they lower the **seizure threshold** during withdrawal.
- They do not address the underlying **autonomic hyperactivity** or GABA-deficiency associated with alcohol cessation.
*Thiamine 100 mg followed by dextrose infusion*
- While vital for preventing **Wernicke-Korsakoff syndrome**, thiamine does not treat the acute symptoms of **autonomic instability** or prevent seizures.
- Dextrose should never be given before **thiamine** in these patients, but this intervention is supportive rather than primary withdrawal management.
*Propranolol 40 mg orally for autonomic symptoms*
- Beta-blockers may mask symptoms of **autonomic arousal** such as tachycardia but do not prevent **seizures** or delirium tremens.
- They are considered **adjunctive therapy** and should not be used as the sole agent for managing acute withdrawal.
*Disulfiram 250 mg daily to prevent relapse*
- Disulfiram is used for **long-term maintenance** of abstinence and is strictly **contraindicated** in the acute phase of withdrawal.
- Administering disulfiram while alcohol is still in the system or during withdrawal can cause a dangerous **disulfiram-ethanol reaction**.
